Evogene (NASDAQ:EVGN) Announces Earnings Results

Evogene (NASDAQ:EVGN – Get Free Report) issued its earnings results on Thursday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.02, FiscalAI reports. Evogene had a negative net margin of 694.18% and a negative return on equity of 156.53%. The firm had revenue of $0.14 million for the quarter, compared to analysts’ expectations of $0.36 million.

Here are the key takeaways from Evogene’s conference call:

  • Evogene said its early acute GVHD drug-discovery program has produced patentable small-molecule candidates with nanomolar biological potency and promising preliminary ADME and toxicology profiles. The program remains at an early stage; the company plans further optimization and expects to begin preclinical work around mid-2027.
  • AgPlenus reported fungicide candidates targeting two previously untapped fungal proteins, with activity against Septoria strains resistant to existing fungicides. In plant-tissue tests, some molecules reduced disease severity by 75% versus untreated controls; greenhouse and field testing are planned as the candidates advance.
  • Evogene reported $9.2 million in cash, cash equivalents, and short-term deposits at September 30, 2026, with quarterly cash usage of about $2.4 million. Nine-month revenue fell to $0.8 million from $3.2 million a year earlier, and the nine-month net loss widened to $10.5 million from $2.5 million.
  • Management said it expects to approach pharmaceutical companies about its drug candidates after further results, potentially around the start of preclinical studies, and to pursue collaboration opportunities for the Septoria program over the coming year. It offered no specific update on progress in its partnered pipeline, saying a fuller pipeline presentation would follow.

Evogene Price Performance

Evogene stock opened at $0.31 on Friday. Evogene has a 52-week low of $0.25 and a 52-week high of $1.26. The firm has a 50-day moving average price of $0.40 and a two-hundred day moving average price of $0.62.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evogene in a report on Friday, October 2nd. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Evogene has a consensus rating of “Sell”.

Get Our Latest Research Report on Evogene

About Evogene

(Get Free Report)

Evogene Ltd. is an Israel-based computational biology company founded in 2002. It uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and computational tools, to discover and develop products for agriculture, human health and other life-science applications. The company advances its work through subsidiaries and collaborations. Its businesses have included Casterra, which develops castor seed varieties, and Lavie Bio, which develops microbiome-based agricultural products.

Featured Stories

Earnings History for Evogene (NASDAQ:EVGN)

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.